CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets.
CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets.
复制标题
DOI：
10.3389/fonc.2021.808396
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Fukayama M
中科院分区：
文献类型：
--
作者：
Kashima J;Hishima T;Okuma Y;Horio H;Ogawa M;Hayashi Y;Horiguchi SI;Motoi T;Ushiku T;Fukayama M
CD70是淋巴细胞上CD27的一种配体蛋白，在多种恶性肿瘤中表达。它是基于抗体治疗的一个有吸引力的靶点，目前正在进行几项临床试验。然而，在胸腺肿瘤的福尔马林固定石蜡包埋（FFPE）组织中，CD70的表达及其与程序性死亡配体-1 （PD-L1）和CD27+肿瘤浸润淋巴细胞（TIL）表达的关系尚无证据。对胸腺鳞状细胞癌（TSCC）（手术标本31例，活检标本11例）、胸腺瘤（60例）、胸腺类癌（3例）、肺鳞状细胞癌（30例）的FFPE组织进行免疫组化分析。根据阳性肿瘤细胞的比例对CD70的免疫反应性进行半定量评分。此外，我们还评估了cd27阳性的TSCC瘤内TIL （iTIL）和间质TIL的密度，并比较了生存率。大多数TSCC病例（87%;27/31）cd70阳性。相比之下，所有胸腺瘤和胸腺类癌均为cd70阴性。LSCC中cd70阳性明显低于TSCC（20%; 6/30）。来自同一患者的活检和切除标本显示出一致的染色模式（6/6患者）。cd70阳性的TSCC比例与CD5（87%）和CD117（90%）相当。观察CD70与PD-L1表达评分的相关性。cd70高表达组和cd70低表达组的生存率无显著差异。与此同时，cd27阳性的高itil肿瘤患者比低itil肿瘤患者的生存率更高。这种倾向在cd70高的亚群中较弱。CD70免疫组化对TSCC的诊断有重要意义。CD70可能通过CD27抑制抗肿瘤免疫。靶向CD70-CD27轴的免疫疗法可能是治疗TSCC的一个有希望的选择。
CD70 – a ligand protein of CD27 on lymphocytes – is expressed in a large spectrum of malignancies. It is an attractive target for antibody-based therapy and several clinical trials are currently being conducted. However, there is no evidence regarding the expression of CD70 and its relationship with expression of programmed death ligand-1 (PD-L1) and CD27+ tumor-infiltrating lymphocytes (TIL) in formalin-fixed paraffin-embedded (FFPE) tissues of thymic tumors. FFPE tissues of thymic squamous cell carcinoma (TSCC) (operative specimens, n = 31; biopsy specimens, n = 11), thymoma (n = 60), thymic carcinoid (n = 3), and lung squamous cell carcinoma (LSCC) (n = 30) were analyzed immunohistochemically. Immunoreactivity for CD70 was semi-quantitatively scored according to the proportion of positive tumor cells. Moreover, the densities of CD27-positive intratumoral TIL (iTIL) and stromal TIL of TSCC were assessed and survival was compared. Most TSCC cases (87%; 27/31) were CD70-positive. In contrast, all thymoma and thymic carcinoid cases were CD70-negative. In LSCC cases, CD70-positivity was significantly lower than TSCC cases (20%; 6/30). Biopsy and resected specimens obtained from the same patients demonstrated a consistent staining pattern (6/6 patients). The proportion of CD70-positive TSCC was comparable with those of CD5 (87%) and CD117 (90%). Correlation between CD70 and PD-L1 expression score was observed. There was no significant difference in survival between the CD70-high and CD70-low expression groups. Meanwhile, patients with CD27-positive iTIL-high tumors exhibited better survival than those with iTIL-low tumors. This tendency was weaker in the CD70-high subset. CD70 immunohistochemistry is useful in diagnosing TSCC. CD70 may prevent anti-tumor immunity via CD27. Immunotherapy targeting the CD70–CD27 axis may be a promising option for the treatment of TSCC.
登录
查看更多内容
CD5和CD117表达在胸部肿瘤中的差异诊断值：1465个非小细胞肺癌病例的大规模研究。
影响因子：
2.6
作者：
Kriegsmann M;Muley T;Harms A;Tavernar L;Goldmann T;Dienemann H;Herpel E;Warth A
通讯作者：
Warth A
DOI：
10.1002/path.5361
发表时间：
2020-02
期刊：
The Journal of pathology
影响因子：
--
作者：
Inaguma S;Lasota J;Czapiewski P;Langfort R;Rys J;Szpor J;Waloszczyk P;Okoń K;Biernat W;Schrump DS;Hassan R;Kasai K;Miettinen M;Ikeda H
通讯作者：
Ikeda H
影响因子：
5.2
作者：
Flieswasser, Tal;Camara-Clayette, Valerie;Jacobs, Julie
通讯作者：
Jacobs, Julie
影响因子：
4.8
作者：
Diegmann, Julia;Junker, Kerstin;von Eggeling, Ferdinand
通讯作者：
von Eggeling, Ferdinand
影响因子：
3.5
作者：
Kaira, Kyoichi;Murakami, Haruyasu;Yamamoto, Nobuyuki
通讯作者：
Yamamoto, Nobuyuki